Practical Strategies for Managing Patients Previously Treated With Efalizumab

Release date: July 2009
Expiration date: July 31, 2010
Estimated time to complete activity: 30 minutes

No longer available for CME credit

Sponsored by Curatio CME Institute

Support for this activity has been provided through educational grants from Amgen and Genentech.

Activity Overview
A 64-year-old female patient presents to your virtual office with psoriasis on her feet. You—in consultation with Jeffrey Weinberg, MD of St. Luke’s-Roosevelt Hospital Center—are managing her care. Among the issues you must consider are reports of progressive multifocal leukoencephalopathy associated with efalizumab treatment, the recent withdrawal of efalizumb from the US market, and the effects of hand and foot psoriasis on quality of life. "Consult" with Dr. Weinberg and your colleagues as you consider treatment options for this patient. This activity follows the progression of this case over several months, solicits your input on key aspects of the case, and presents treatment recommendations provided by other clinicians that have "consulted" on this case.

Target Audience
This activity has been designed to meet the educational needs of dermatologists and other health care professionals involved in the care of patients with psoriasis.

Learning Objectives
Upon completion of this activity, participants should be able to:

Develop treatment strategies for difficult-to-manage psoriasis cases, including combination systemic therapy, transitioning to biologic agents, and transitioning between biologic agents
Formulate a practical plan for managing moderate to severe psoriasis, taking into consideration complex patient characteristics
Recognize long-term safety issues associated with biologic agents used to treat psoriasis

Faculty

Jeffrey M. Weinberg, MD
Assistant Clinical Professor of Dermatology
Columbia University College of Physicians and Surgeons
Director, Clinical Research Center
St. Luke’s-Roosevelt Hospital Center
New York, New York

Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period July 2009–July 31, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.

Media
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.

Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Jeffrey M. Weinberg, MD, has disclosed the following relevant financial relationships:

Speaker	Abbott, Amgen, Astellas, Centocor Ortho Biotech, Genentech
Researcher	Abbott

Curatio CME Institute
Shari J. Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.

Disclaimer
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Amgen, and Genentech do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Amgen, or Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

JavaScript-enabled Interner browser

Contact Information
PsoriasisTx.com
100 Campbell Boulevard
Suite 103
Exton, PA 19341
editor@psoriasistx.com

Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of PsoriasisTx.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.

Curatio CME Institute does not require individuals to register to use PsoriasisTx.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on PsoriasisTx.com

Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.

Information gathered through PsoriasisTx.com will not be released to any other company or organization for any purpose; this information remains confidential.

Curatio CME Institute uses Web site tracking software to determine how PsoriasisTx.com is used. This information helps Curatio CME Insitute determine the best strategies for improving PsoriasisTx.com and better meeting the needs of its users. This software does not identify individual users.

If you have any questions about PsoriasisTx.com or any Curatio CME Institute policies, you may contact us at info@psoriasistx.com.

Thank you for using PsoriasisTx.com.

PsoriasisTx.com

Practical Strategies for Managing Patients Previously Treated With Efalizumab

Begin CME Activity

Sign in